Please assess the completion status of the following clinical trial:

Trial Title: A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants Age 12 to 15 Years:~* Participant is in good health~* Parent/legal guardian and participant agree to provide study personnel with a primary telephone number for follow-up~* Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1~* Participant has not received any other HPV vaccine~* Participant is not yet sexually active~Participants Age 16 to 26 Years:~* Participant is in good health~* Participant agrees to provide a primary telephone number for follow-up~* Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1~* Participant has not received any other HPV vaccine~* Participant has never had Papanicolaou (Pap) testing or has only had normal results~* Participant has a history of 0 to 4 lifetime sexual partners at enrollment~Exclusion Criteria:~All participants:~* Participant has a history of severe allergic reaction that required medical intervention~* Participant has any disorder that would contraindicate intramuscular injections~* Participant is pregnant~* Participant is immunocompromised or has an autoimmune condition~* Participant has had a splenectomy~* Participant has received any immune globulin product or blood-derived product~* Participant has participated in a HPV vaccine clinical trial~Participants Age 16 to 26 Only:~* Participant expects to donate eggs during the study~* Participant has a history of abnormal cervical biopsy result~* Participant has a history of HPV-related external genital lesions, external genital cancer, HPV-related vaginal lesions, or vaginal cancer

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- 9vHPV Vaccine (Type: EXPERIMENTAL): Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
- Placebo (Type: PLACEBO_COMPARATOR): Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.

Based on this trial design, predict the completion outcome and termination type (if applicable).